Lisata Therapeutics
LSTA
21 hedge funds and large institutions have $2.33M invested in Lisata Therapeutics in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 1 closing their positions.
136% more capital inflows, than outflows
Capital inflows: $94.4K | Capital outflows: $40K
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
5% more funds holding
Funds holding: 20 → 21 (+1)
0.15% more ownership
Funds ownership: 9.21% → 9.35% (+0.15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$66.6K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$22.6K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.99K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$1.11K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$612 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$33.1K |
| 2 |
Renaissance Technologies
New York
|
-$6.58K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$355 |
| 4 |
Barclays
London,
United Kingdom
|
-$9 |
LSTA Hedge Fund Activity: Q4 2024 in Review
21 of the 7,623 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2024, worth a combined $2.33M — up 1.7% from $2.3M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LSTA positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $66.6K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $33.1K sold.
- 21 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2024, up from 20 in Q3 2024.
- Funds reported $2.33M of Lisata Therapeutics stock for Q4 2024, up 1.7% quarter-over-quarter.
- 2 funds opened new Lisata Therapeutics positions in Q4 2024 and 1 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q4 2024 was Citadel Advisors, an estimated $66.6K added.
- The largest Lisata Therapeutics seller in Q4 2024 was Susquehanna International Group, an estimated $33.1K sold.
Based on aggregated 13F filings for Q4 2024.